Ginkgo Bioworks Holdings Inc (NYSE: DNA) on Monday, soared 15.08% from the previous trading day, before settling in for the closing price of $5.57. Within the past 52 weeks, DNA’s price has moved between $5.00 and $47.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 76.14%. The company achieved an average annual earnings per share of 49.93%. With a float of $36.98 million, this company’s outstanding shares have now reached $42.70 million.
Considering the fact that the conglomerate employs 834 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 67.97%, operating margin of -238.06%, and the pretax margin is -241.15%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ginkgo Bioworks Holdings Inc is 32.80%, while institutional ownership is 57.91%. The most recent insider transaction that took place on Apr 07 ’25, was worth 511. Before that another transaction happened on Apr 04 ’25, when Company’s Officer proposed sale 99 for $5.50, making the entire transaction worth $544.
Ginkgo Bioworks Holdings Inc (DNA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.93% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 48.92% during the next five years compared to -27.97% drop over the previous five years of trading.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Ginkgo Bioworks Holdings Inc (DNA) is currently performing well based on its current performance indicators. A quick ratio of 5.62 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -10.62, a number that is poised to hit -1.55 in the next quarter and is forecasted to reach -3.73 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Compared to the last year’s volume of 1.66 million, its volume of 1.67 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 33.74%. Additionally, its Average True Range was 0.80.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 11.90%, which indicates a significant decrease from 50.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.86% in the past 14 days, which was lower than the 115.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.54, while its 200-day Moving Average is $9.64. Nevertheless, the first resistance level for the watch stands at $6.97 in the near term. At $7.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.49. If the price goes on to break the first support level at $5.45, it is likely to go to the next support level at $4.49. Should the price break the second support level, the third support level stands at $3.93.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
Market capitalization of the company is 372.00 million based on 58,034K outstanding shares. Right now, sales total 227,040 K and income totals -547,030 K. The company made 43,850 K in profit during its latest quarter, and -107,530 K in sales during its previous quarter.
